<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02965326</url>
  </required_header>
  <id_info>
    <org_study_id>ABCF-2016-01</org_study_id>
    <secondary_id>2016-A00309-42</secondary_id>
    <nct_id>NCT02965326</nct_id>
  </id_info>
  <brief_title>Surrogate Markers of Response to New Therapies in Cystic Fibrosis Patients</brief_title>
  <acronym>BIO-CFTR</acronym>
  <official_title>Personalized Therapy of Cystic Fibrosis: Set-up of Response Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Necker-Enfants Malades</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association Mucoviscidose-ABCF2</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vaincre la Mucoviscidose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hôpital Necker-Enfants Malades</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which biological marker, or association of
      biological markers, best predict clinical response of cystic fibrosis patients to CFTR
      modulators.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is based upon the hypothesis that clinical response of cystic fibrosis patients to
      CFTR modulators is correlated to in vitro responses to these drugs of epithelial cells
      derived from the patients, as assessed by CFTR-dependent Chloride secretion. Epithelial cells
      will be derived either from nasal or rectal epithelia, and consist both of cultured cells and
      organoids. The drugs tested will be Ivacaftor, or Lumacaftor/Ivacaftor, according to
      patient's treatment. Results of these assays will be compared with response to treatment at 6
      and 12 months, assessed by clinical response and in vivo assay of CFTR function.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between biological markers and clinical and physiological outcome</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between biological markers and clinical and physiological outcome</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Cystic fibrosis, treated</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cystic fibrosis patients treated either by Ivacaftor or by the association Ivacaftor-Lumacaftor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cystic fibrosis, non treated</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cystic fibrosis patients, non treated by a CFTR modulator</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-Cystic fibrosis</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by physiological and genetic investigations</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Nasal swab; rectal biopsy.</intervention_name>
    <description>Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.</description>
    <arm_group_label>Cystic fibrosis, treated</arm_group_label>
    <arm_group_label>Cystic fibrosis, non treated</arm_group_label>
    <arm_group_label>Non-Cystic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis patients treated by CFTR modulators (Ivacaftor or the association
             Ivacaftor-Lumacaftor)

          -  Cystic fibrosis patients non treated by CFTR modulators

          -  Patients in whom cystic fibrosis diagnosis has been suspected, but excluded by
             physiological and genetic investigations

        Exclusion Criteria:

          -  pregnant or lactating women

          -  contraindication to nasal swab

          -  contraindication to rectal biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabelle Sermet, MD, PhD</last_name>
    <phone>33 1 44 49 48 87</phone>
    <email>isabelle.sermet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Louis Pérignon, MD, PhD</last_name>
    <email>jean-louis.perignon@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Necker Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SERMET Isabelle, Professor</last_name>
      <phone>01 44 49 48 87</phone>
      <email>isabelle.sermet@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>SERMET Isabelle, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, Konstan MW, Moss R, Ratjen F, Sermet-Gaudelus I, Rowe SM, Dong Q, Rodriguez S, Yen K, Ordoñez C, Elborn JS; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011 Nov 3;365(18):1663-72. doi: 10.1056/NEJMoa1105185.</citation>
    <PMID>22047557</PMID>
  </reference>
  <reference>
    <citation>Graeber SY, Hug MJ, Sommerburg O, Hirtz S, Hentschel J, Heinzmann A, Dopfer C, Schulz A, Mainz JG, Tümmler B, Mall MA. Intestinal Current Measurements Detect Activation of Mutant CFTR in Patients with Cystic Fibrosis with the G551D Mutation Treated with Ivacaftor. Am J Respir Crit Care Med. 2015 Nov 15;192(10):1252-5. doi: 10.1164/rccm.201507-1271LE.</citation>
    <PMID>26568242</PMID>
  </reference>
  <reference>
    <citation>Quittner A, Suthoff E, Rendas-Baum R, Bayliss MS, Sermet-Gaudelus I, Castiglione B, Vera-Llonch M. Effect of ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation: patient-reported outcomes in the STRIVE randomized, controlled trial. Health Qual Life Outcomes. 2015 Jul 2;13:93. doi: 10.1186/s12955-015-0293-6.</citation>
    <PMID>26135562</PMID>
  </reference>
  <reference>
    <citation>De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, Higgins M. Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation. J Cyst Fibros. 2014 Dec;13(6):674-80. doi: 10.1016/j.jcf.2014.09.005. Epub 2014 Sep 26.</citation>
    <PMID>25266159</PMID>
  </reference>
  <reference>
    <citation>Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, Rodman D; VX09-809-102 study group. A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. Lancet Respir Med. 2014 Jul;2(7):527-38. doi: 10.1016/S2213-2600(14)70132-8. Epub 2014 Jun 24.</citation>
    <PMID>24973281</PMID>
  </reference>
  <reference>
    <citation>Wainwright CE, Elborn JS, Ramsey BW, Marigowda G, Huang X, Cipolli M, Colombo C, Davies JC, De Boeck K, Flume PA, Konstan MW, McColley SA, McCoy K, McKone EF, Munck A, Ratjen F, Rowe SM, Waltz D, Boyle MP; TRAFFIC Study Group; TRANSPORT Study Group. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med. 2015 Jul 16;373(3):220-31. doi: 10.1056/NEJMoa1409547. Epub 2015 May 17.</citation>
    <PMID>25981758</PMID>
  </reference>
  <reference>
    <citation>De Boeck K, Kent L, Davies J, Derichs N, Amaral M, Rowe SM, Middleton P, de Jonge H, Bronsveld I, Wilschanski M, Melotti P, Danner-Boucher I, Boerner S, Fajac I, Southern K, de Nooijer RA, Bot A, de Rijke Y, de Wachter E, Leal T, Vermeulen F, Hug MJ, Rault G, Nguyen-Khoa T, Barreto C, Proesmans M, Sermet-Gaudelus I; European Cystic Fibrosis Society Clinical Trial Network Standardisation Committee. CFTR biomarkers: time for promotion to surrogate end-point. Eur Respir J. 2013 Jan;41(1):203-16. doi: 10.1183/09031936.00057512. Epub 2012 Aug 9. Review.</citation>
    <PMID>22878883</PMID>
  </reference>
  <reference>
    <citation>Dekkers JF, Wiegerinck CL, de Jonge HR, Bronsveld I, Janssens HM, de Winter-de Groot KM, Brandsma AM, de Jong NW, Bijvelds MJ, Scholte BJ, Nieuwenhuis EE, van den Brink S, Clevers H, van der Ent CK, Middendorp S, Beekman JM. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nat Med. 2013 Jul;19(7):939-45. doi: 10.1038/nm.3201. Epub 2013 Jun 2.</citation>
    <PMID>23727931</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2016</study_first_submitted>
  <study_first_submitted_qc>November 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2016</study_first_posted>
  <last_update_submitted>December 2, 2017</last_update_submitted>
  <last_update_submitted_qc>December 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Necker-Enfants Malades</investigator_affiliation>
    <investigator_full_name>Isabelle Sermet-Gaudelus</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

